US equities |
SPCX $168.16 ▲+5.79% NVDA $237.19 ▲+1.38% MU $1,064.02 ▼-1.01% TSLA $378.31 ▲+2.08% MSFT $525.88 ▲+1.61% INTC $116.85 ▼-2.08% SNDK $1,720.40 ▲+0.02% META $745.36 ▲+2.37%
FinancialContent

Articles published by Precision BioSciences, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
News headline image
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
< Previous 1 2 3 4 5 6 Next >